In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Treating patients with HFpEF: what progress are we making?
Session

Event : ESC Congress 2019

Topic : Chronic Heart Failure

  • Session type : Satellite Symposium
  • Date : 01 September 2019
  • Time : 18:15 - 19:15
  • Sponsored by Novartis Pharma AG

5 presentations in this session

Welcome and introduction

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : CS Lam (Singapore,SG)
  • Sponsored by Novartis Pharma AG

Is HFpEF the largest unmet need in cardiology?

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : JJV McMurray (Glasgow,GB)
  • Sponsored by Novartis Pharma AG

Is a breakthrough treatment for patients with HFpEF within reach?

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : S Solomon (Boston,US)
  • Sponsored by Novartis Pharma AG

Discussions, questions and answers

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : CS Lam (Singapore,SG), JJV McMurray (Glasgow,GB), S Solomon (Boston,US)
  • Sponsored by Novartis Pharma AG

Key learnings and close

Event : ESC Congress 2019

  • Session : Treating patients with HFpEF: what progress are we making?
  • Speaker : CS Lam (Singapore,SG)
  • Sponsored by Novartis Pharma AG

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are